Verastem has dosed the first patient in its Phase 2 TARGET-D 203 trial of VS-7375 for KRAS G12D-mutated metastatic colorectal cancer. The milestone means all th

BWB News TV • 2026-07-28 20:11 UTC • By Billy Odell Tucker-Robinson

Verastem has dosed the first patient in its Phase 2 TARGET-D 203 trial of VS-7375 for KRAS G12D-mutated metastatic colorectal cancer. The milestone means all three registration-directed Phase 2 studies for the candidate are now underway.

Share this article

𝕏 X / Twitter Facebook LinkedIn WhatsApp

📚 More from Billy’s World

📰 Banking With Billy News All breaking financial news & market analysis 📚 Banking With Billy Books Deep-dive books on every financial story 💬 Join the Community discord.gg/VHxwmR5j4Y 🎥 Banking With Billy on YouTube Live streams & market commentary

Banking With Billy News Network — bankingwithbilly.com
Discord: discord.gg/VHxwmR5j4Y • YouTube: @BankingWithBilly